Trials / Unknown
UnknownNCT03496272
Atrial Fibrillation Cycle Length Measured on Transesophageal Echocardiography
Atrial Fibrillation (AF) Cycle Length Measured on Transesophageal Echocardiography : a Feasible Parameter for Predicting the Recurrence of AF in Patients With AF Converted to Sinus Rhythm After DC Cardioversion
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Pusan National University Yangsan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Background: The atrial fibrillation cycle length (AFCL) measured by electrophysiologic study is well known parameter for the maintenance of sinus rhythm after DC cardioversion (DCCV) or ablation therapy. The aim of this study was to test whether a AFCL measured by transesophageal echocardiography (AFCLTEE) could predict the outcome after DCCV. Methods: In 100 consecutive patients with non-valvular AF, TEE will be performed within 6 hours before DCCV. The AFCLTEE was measured by averaging 10 sequential peak to peak intervals of atrial fibrillary waves seen in the pulsed wave Doppler image on the left atrial appendage. The primary endpoint was AF free survival rate at 6 months after DCCV.
Conditions
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2020-12-31
- Completion
- 2021-06-30
- First posted
- 2018-04-12
- Last updated
- 2018-04-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03496272. Inclusion in this directory is not an endorsement.